MRNA vs. SGEN, AMGN, GILD, BIIB, BNTX, ARGX, NBIX, TECH, QGEN, and RGEN
Should you be buying Moderna stock or one of its competitors? The main competitors of Moderna include Seagen (SGEN), Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), BioNTech (BNTX), argenx (ARGX), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), and Repligen (RGEN). These companies are all part of the "medical" sector.
Moderna (NASDAQ:MRNA) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings.
75.3% of Moderna shares are held by institutional investors. Comparatively, 84.3% of Seagen shares are held by institutional investors. 15.7% of Moderna shares are held by insiders. Comparatively, 25.9% of Seagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Seagen has lower revenue, but higher earnings than Moderna. Seagen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Moderna presently has a consensus price target of $126.46, indicating a potential downside of 11.29%. Seagen has a consensus price target of $229.00, indicating a potential upside of 0.11%. Given Seagen's higher possible upside, analysts clearly believe Seagen is more favorable than Moderna.
Seagen has a net margin of -32.61% compared to Moderna's net margin of -115.82%. Moderna's return on equity of -20.10% beat Seagen's return on equity.
In the previous week, Moderna had 39 more articles in the media than Seagen. MarketBeat recorded 40 mentions for Moderna and 1 mentions for Seagen. Moderna's average media sentiment score of 0.52 beat Seagen's score of 0.00 indicating that Moderna is being referred to more favorably in the media.
Seagen received 554 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 62.12% of users gave Seagen an outperform vote while only 57.77% of users gave Moderna an outperform vote.
Moderna has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Seagen has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.
Summary
Moderna and Seagen tied by winning 9 of the 18 factors compared between the two stocks.
Get Moderna News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
